Core Insights - Gelteq Limited has initiated a preclinical animal trial in collaboration with Monash University to evaluate its proprietary formulation technology aimed at improving the oral delivery of oily and poorly soluble drugs [1][2][3] Company Overview - Gelteq is a clinical and science-based company headquartered in Melbourne, Australia, focusing on gel-based oral delivery solutions for various applications, including prescription drugs and nutraceuticals [4] Industry Context - Over 40% of marketed drugs and up to 90% of discovery candidates face challenges related to low solubility and variable bioavailability, which can lead to higher dosing and increased side effects [2] - Pharmaceutical companies invest more than USD 4 billion annually in technologies to enhance the delivery of oily and poorly soluble drugs, with strong projected growth through 2030 [2][8] Potential Commercial Applications - If successful in the trial, Gelteq aims to assist clients with a portfolio of oily and poorly soluble drugs through various commercial options, including pipeline salvage and lifecycle extension [3][6] - The company’s formulation technology could potentially improve adherence by reducing active pharmaceutical ingredient (API) dose size and food-effect dependence, leading to fewer side effects and more consistent patient outcomes [6]
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform